Observational Study Evaluating Ubrogepant for Treating Migraine in Adults During Prodrome Phase

What this Trial Is About

Migraine is a neurological condition marked by moderate to severe headaches, often accompanied by nausea, vomiting, and sensitivity to light and sound. This research evaluates changes in migraine attack severity among adults using oral ubrogepant during migraine attacks. The study will include about 189 adult participants across approximately 15 sites in the US. Participants will take ubrogepant as prescribed by their physicians according to routine clinical practice and local approved guidelines. This observational study involves no experimental treatment changes and follows participants for up to 13 weeks. During this time, participants receive their usual migraine care without additional intervention. Participants will attend regular visits at hospitals or clinics as part of their routine care during the study period. Researchers will monitor the percentage of participants experiencing absence of moderate to severe headache over 24 hours after dosing during the prodrome phase of migraine attacks. The study aims to track real-world effectiveness without adding extra burden to participants.

Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks